You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1392 EVOLVE-104, a novel ULBP2-targeted T cell engager that integrates CD2 costimulation for the treatment of basal and squamous lineage tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to July 2025

AbstractFullPdf
Nov 2023244026
Dec 2023154042
Jan 202459010
Feb 202496010
Mar 2024106019
Apr 2024102016
May 202482017
Jun 202484013
Jul 2024142016
Aug 202440011
Sep 20246205
Oct 2024188023
Nov 2024254032
Dec 2024154025
Jan 2025190028
Feb 202571025
Mar 20252025
Apr 20250023
May 20250020
Jun 20251011
Jul 2025001
Total20310398